Interaction of the β adrenergic receptor antagonist bucindolol with serotonergic receptors

Journal of Cardiovascular Pharmacology

Volumn 35, Issue 1, 2000, Pages 29-36

  Watts, Stephanie W ^a   Fink, Gregory D ^a   Silver, Paul J ^b   Gushing, Daniel J ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b IBEX Technologies Corporation

^c Astra Merck Inc   (United States)

Author keywords

5 HT; Bucindolol; Receptor; Vasodilation

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CYANOPINDOLOL; PHENYLEPHRINE; PROSTAGLANDIN F2 ALPHA; SEROTONIN 1A RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN RECEPTOR;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; BRADYCARDIA; CONTROLLED STUDY; CORONARY ARTERY; DRUG MECHANISM; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SEROTONINERGIC SYSTEM; VASCULAR ENDOTHELIUM; VASODILATATION;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AORTA, THORACIC; CORONARY VESSELS; GASTRIC FUNDUS; HEMODYNAMIC PROCESSES; MALE; PHENYLEPHRINE; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STEREOISOMERISM; SWINE;

EID: 0033989292     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200001000-00004     Document Type: Article

References (6)

1. Hershberger RE, Wynn JR, Sundberg L, Bristow MR. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 1990;15:959-67.
2. Hjalmarson A, Kneider M, Waagstein F. The role of beta-blockers in left ventricular dysfunction and heart failure. Drugs 1997;54: 501-10.
3. Bristow MR, Abraham WT, Yoshikawa T, et al. Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovasc Drugs Ther 1997;11:291-6.
4. The BEST Steering Committee. Design of the beta-blocker evaluation survival trial (BEST). Am J Cardiol 1995;75:1220-3.
5. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy: bucindolol investigators. Circulation 1994;89:1632-42.
6. Anderson JL, Gilbert EM, O'Connell JB, et al. Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1991:17:1373-81.